Moderna announces mrna-1345, an investigational respiratory syncytial virus (rsv) vaccine, has met primary efficacy endpoints in phase 3 trial in older adults

Mrna-1345 demonstrated vaccine efficacy of 83.7% against rsv lower respiratory tract disease, defined by 2 or more symptoms in older adults mrna-1345 was generally well-tolerated, with no safety concerns identified by the dsmb based on these results, moderna intends to submit mrna-1345 for regulatory approval cambridge, ma, accesswire / january 17, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced positive topline data from its conquerrsv phase 3 pivotal efficacy trial of mrna-1345, an investigational mrna vaccine targeting respiratory syncytial virus (rsv) in older adults. following review by an independent data and safety monitoring board (dsmb), the primary efficacy endpoints have been met, including vaccine efficacy (ve) of 83.7% (95.88% ci: 66.1%, 92.2%; p
MRNA Ratings Summary
MRNA Quant Ranking